Midtown Manhattan skyline.

The inaugural CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference took place September 16-19, 2015, in New York, New York.

Treating EBV-associated lymphomas with VSTs

Print Friendly, PDF & Email


EBV-infected_cell_210.jpg
An EBV-infected cell (green/red)
among uninfected cells (blue)
Image by Benjamin
Chaigne-Delalande

Type 2 Epstein-Barr virus (EBV) tumors, such as Hodgkin and non-Hodgkin lymphomas, are challenging to treat with virus-specific T (VST) cells, according to researchers. These lymphomas express a more restricted array of EBV antigens that are not particularly immunogenic. Nevertheless,... [Read Article]

Print Friendly, PDF & Email

Creating off-the-shelf VSTs

Print Friendly, PDF & Email


Heslop_Helen_MD_Baylor.jpeg
Helen Heslop, MD
Photo courtesy of Baylor
College of Medicine

Researchers are creating virus-specific T cells (VST) to treat and prevent viral infections in patients who undergo hematopoietic stem cell transplant. Thus far, the group has modified T cells with 5 viral vectors—Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (ADV), BK virus (BKV), and human herpesvirus... [Read Article]

Print Friendly, PDF & Email

New chimeric CD19 antibody may reduce MRD in ALL

Print Friendly, PDF & Email


Seidel_Ursula_CRI-AACR_rev-240.jpg
Ursula Seidel

Researchers have developed a pharmaceutical-grade, third-generation, CD19-specific antibody that reduced minimal residual disease (MRD) in pediatric patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This chimerized, Fc-optimized antibody—4G7SDIE—was used on a compassionate-need basis in 14 patients with relapsed or refractory BCP-ALL. Nine of the patients had prior stem cell transplants.

... [Read Article]
Print Friendly, PDF & Email

Nonviral gene transfer of CARs tested in humans

Print Friendly, PDF & Email


Cooper_Laurence_MD_Anderson_230.jpg
Laurence Cooper, MD, PhD
Photo courtesy of MDACC

Researchers have used a nonviral approach to create chimeric antigen receptor (CAR) T cells and tested these cells in safety trials. Patients with advanced lymphoma or leukemia were infused with the nonvirally modified CD19-directed CAR T cells after autologous or allogeneic hematopoietic stem cell transplant (HSCT).... [Read Article]

Print Friendly, PDF & Email

Abs from transplanted AML patients enhance GvL effect in vitro

Print Friendly, PDF & Email


Mette_Hazenberg_MD-PhD-rev-240.jpg
Mette Hazenberg, MD, PhD

Investigators have found that B cells may play a role in stimulating graft-versus-leukemia (GvL) responses in patients with acute myeloid leukemia (AML) who have undergone allogeneic hematopoietic stem cell transplant (HSCT). The team created B cell lines from these patients, isolated AML-specific antibodies, and found that these antibodies can induce the... [Read Article]

Print Friendly, PDF & Email

Insights from the 5-year follow-up of CTL019 in CLL

Print Friendly, PDF & Email


june-carl-md-penn-med-220.jpg
Carl June, MD
Photo courtesy of the
University of Pennsylvania

The 5-year follow-up of the phase 1 trial of CTL019 in relapsed or refractory chronic lymphoblastic leukemia (CLL) is allowing investigators to define more clearly who will respond to chimeric antigen receptor (CAR) T cells directed against CD19. One thing investigators have determined... [Read Article]

Print Friendly, PDF & Email

CAR T-cell therapy tested in Sweden

Print Friendly, PDF & Email


Karlsson_Hannah_PhD_CRI-AACR2015.jpg
Hannah Karlsson, PhD

For the first time, according to researchers, chimeric antigen receptor (CAR) T-cell therapy has been tested in a clinical trial in Sweden. Early results have shown the treatment can produce complete responses (CRs) in leukemia and lymphoma, although most patients ultimately progressed. Hannah Karlsson, PhD, of Uppsala University in Sweden, presented these... [Read Article]

Print Friendly, PDF & Email